Answer:
Micro-environment factors include internal factors i.e. customers, suppliers, competitors, etc. whereas macro-environment has external factors like political, social, economic, etc.

studiousguy.com › Marketing
Brian should <span>use the Bid Simulator
Adword's bid simulator will allow you to know what's changes gonna exist in your advertising campaign if you change a certain factors in your campaign.
Using this tool will provide you with Potential CPC amounts from a certain amount of bids.</span>
Answer:
Prepare the necessary entry to clear the Intangible Assets account and to set up separate accounts for distinct types of intangibles.
- Dr Patents 387,900
- Cr Intangible assets 387,900
- Dr Goodwill 341,000
- Cr Intangible assets 341,000
- Dr Franchises 421,000
- Cr Intangible assets 421,000
- Dr Copyright 145,200
- Cr Intangible assets 145,200
- Dr Research and development expense 211,000
- Cr Intangible assets 211,000
Make the entry as of December 31, 2020, recording any necessary amortization:
- Dr Patents 387,900
- Cr Intangible assets 387,900
- Dr Amortization expense 43,100
- Cr Accumulated amortization - Patents 43,100
- Dr Goodwill 341,000
- Cr Intangible assets 341,000
- Dr Franchises 421,000
- Cr Intangible assets 421,000
- Dr Amortization expense 42,100
- Cr Accumulated amortization - Franchises 43,100
- Dr Copyright 145,200
- Cr Intangible assets 145,200
- Dr Amortization expense 29,040
- Cr Accumulated amortization - Copyright 29,040
*R&D costs are expenses, they are not amortized.
Reflect all balances accurately as of December 31, 2020. Use straight-line amortization
.
- Patents $344,800
- Goodwill $341,000
- Franchises $378,900
- Copyright $116,160
Answer:
The correct answer is letter "A": low.
Explanation:
The marginal cost of a company represents the cost of producing one more additional unit. For knowledge-intensive industries such as pharmaceuticals that require clearance from the <em>Food and Drug Administration</em> (FDA), investment for research, development and to produce drugs is high, but once the drugs are already in production the marginal cost tends to be low.
